Spotlight Stories
-
Building New Solutions For 2023 In Manufacturing And Supply Chain
12/1/2022
In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.
-
Pioneering In-House, Continuous Manufacturing
11/1/2022
Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.
-
Fueling A Focused Drug Development Model
11/1/2022
Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end, and commercialization on the other.
-
Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising
11/1/2022
The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.
-
Managing Through Mixed Trial Results And An Economic Downturn
11/1/2022
From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory approval, Cary Claiborne has been faced with multiple challenges since becoming CEO of Adial Pharma in August.
-
Imagine Pharma’s Multilayered Path To Market
10/3/2022
From the looks of its modest open floor plan lab in Pittsburgh’s uptown, it might not be obvious to the casual observer that Imagine Pharma and its nine-person full-time workforce are developing multiple pharmaceutical products across three distinct platforms.
-
The Discovering CEO
10/3/2022
In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.
-
Nonprofit Pursues Oncology Drugs
9/1/2022
RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.
-
Conducting A Drug Development Orchestra To Treat Mental Illness
9/1/2022
Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric drugs discovered through a modular constellation of CRO partners.
-
Bayer Brings External Innovation Inside, With Guardrails
9/1/2022
Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?